**Core Concept**
Luteinizing hormone-releasing hormone (LHRH) analogues are synthetic derivatives of decapeptides that mimic the action of native GnRH, leading to an initial surge in gonadotropin release followed by downregulation of GnRH receptors and decreased production of testosterone.

**Why the Correct Answer is Right**
Buserelin is a potent LHRH analogue that binds to GnRH receptors in the pituitary gland, stimulating an initial increase in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. However, continuous exposure to Buserelin leads to receptor downregulation and internalization, resulting in decreased LH and FSH secretion. This decrease in gonadotropin release subsequently reduces testosterone production, making it an effective treatment for prostate cancer.

**Why Each Wrong Option is Incorrect**
* **Option A:** Goserelin is another LHRH analogue used in the treatment of prostate cancer, but it is not the answer to this specific question.
* **Option C:** Triptorelin is an LHRH analogue used in the treatment of hormone-sensitive cancers, including prostate cancer, but it is not the correct answer.
* **Option D:** Leuprorelin is a synthetic LHRH analogue used in the treatment of hormone-sensitive cancers, including prostate cancer, but it is not the correct answer.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that LHRH analogues can initially cause a surge in testosterone production, which may exacerbate symptoms in patients with hormone-sensitive cancers. Therefore, it's crucial to monitor patients closely during the initiation of LHRH analogue therapy.

**Correct Answer:** B. Buserelin